Germany’s Merck KGaA (MRK: DE) has announced that US and EU inspectors have given the all clear to its Californian factory for the production of BioReliance viral and gene therapy products.
The company's Carlsbad facility underwent a major expansion in 2016, and is now nearly double its former production capacity.
Merck said the facility will enable one of its key customers to launch novel gene therapies in both the USA and in Europe, which are currently under review by both the US Food and Drug Administration and European Medicines Agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze